These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33631988)

  • 21. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.
    van Meer PJ; Kooijman M; Brinks V; Gispen-de Wied CC; Silva-Lima B; Moors EH; Schellekens H
    MAbs; 2013; 5(5):810-6. PubMed ID: 23924803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies.
    Herzyk DJ; Haggerty HG
    AAPS J; 2018 Feb; 20(2):28. PubMed ID: 29417397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
    Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
    Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Old to new ligand-binding assay method modifications.
    Stouffer B; Stocker D
    Bioanalysis; 2016 Jul; 8(13):1403-7. PubMed ID: 27302308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.
    Namdari R; Jones K; Chuang SS; Van Cruchten S; Dincer Z; Downes N; Mikkelsen LF; Harding J; Jäckel S; Jacobsen B; Kinyamu-Akunda J; Lortie A; Mhedhbi S; Mohr S; Schmitt MW; Prior H
    Regul Toxicol Pharmacol; 2021 Nov; 126():105029. PubMed ID: 34455009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.
    Lynch CM; Hart BW; Grewal IS
    MAbs; 2009; 1(1):2-11. PubMed ID: 20046568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics.
    de Zafra CLZ; Sasseville VG; Matsumoto S; Freichel C; Milton M; MacLachlan TK; Farman C; Raymond I; Gupta S; Newton R; Atzpodien EA; Thackaberry EA
    Regul Toxicol Pharmacol; 2017 Jun; 86():221-230. PubMed ID: 28322894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods.
    Tsaioun K; Blaauboer BJ; Hartung T
    ALTEX; 2016; 33(4):343-358. PubMed ID: 27806179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Absorption, distribution, metabolism, excretion and toxicity of biologics and its application in pharmacokinetic modeling].
    Zhang CF; Xie HT; Pan GY
    Yao Xue Xue Bao; 2016 Aug; 51(8):1202-8. PubMed ID: 29897713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early development of therapeutic biologics--pharmacokinetics.
    Baumann A
    Curr Drug Metab; 2006 Jan; 7(1):15-21. PubMed ID: 16454690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementation challenges for designing integrated in vitro testing strategies (ITS) aiming at reducing and replacing animal experimentation.
    De Wever B; Fuchs HW; Gaca M; Krul C; Mikulowski S; Poth A; Roggen EL; Vilà MR
    Toxicol In Vitro; 2012 Apr; 26(3):526-34. PubMed ID: 22269383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The Identification of Critical Quality Attributes (CQAs) for the Development of Antibody Drugs].
    Saitoh S
    Yakugaku Zasshi; 2018; 138(12):1475-1481. PubMed ID: 30504661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
    Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
    Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation and clinical relevance of animal models for inhaled pharmaceuticals and biopharmaceuticals.
    Sécher T; Bodier-Montagutelli E; Guillon A; Heuzé-Vourc'h N
    Adv Drug Deliv Rev; 2020 Dec; 167():148-169. PubMed ID: 32645479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing the Reuse of Protein Non-Naïve Nonhuman Primates in Pharmaceutical Drug Discovery and Development: An Overview and Industry Position on the Challenges and Benefits.
    Mattis C; Bratcher N; Burns M; Carosino C; de Zafra C; Fancher RM; Georgi K; Graff C; Hukkanen RR; Johnson C; Lao Y; Lange A; Lee D; Lepherd M; Maguire S; Malisauskas M; Manuel M; Miranda S; Reed L; Santos R; Sayers B; Shaw D; Shuster D
    Int J Toxicol; 2022 Aug; 41(4):291-296. PubMed ID: 35656559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonclinical safety evaluation of biotechnologically derived pharmaceuticals.
    Dempster AM
    Biotechnol Annu Rev; 2000; 5():221-58. PubMed ID: 10875002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling.
    Passot C; Pouw MF; Mulleman D; Bejan-Angoulvant T; Paintaud G; Dreesen E; Ternant D
    Ther Drug Monit; 2017 Aug; 39(4):322-326. PubMed ID: 28703717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing drug discovery by Investigative Toxicology: Current and future trends.
    Beilmann M; Boonen H; Czich A; Dear G; Hewitt P; Mow T; Newham P; Oinonen T; Pognan F; Roth A; Valentin JP; Van Goethem F; Weaver RJ; Birk B; Boyer S; Caloni F; Chen AE; Corvi R; Cronin MTD; Daneshian M; Ewart LC; Fitzgerald RE; Hamilton GA; Hartung T; Kangas JD; Kramer NI; Leist M; Marx U; Polak S; Rovida C; Testai E; Van der Water B; Vulto P; Steger-Hartmann T
    ALTEX; 2019; 36(2):289-313. PubMed ID: 30570669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.